JP2023522193A5 - - Google Patents

Info

Publication number
JP2023522193A5
JP2023522193A5 JP2022562752A JP2022562752A JP2023522193A5 JP 2023522193 A5 JP2023522193 A5 JP 2023522193A5 JP 2022562752 A JP2022562752 A JP 2022562752A JP 2022562752 A JP2022562752 A JP 2022562752A JP 2023522193 A5 JP2023522193 A5 JP 2023522193A5
Authority
JP
Japan
Application number
JP2022562752A
Other languages
Japanese (ja)
Other versions
JPWO2021209775A5 (https=
JP2023522193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2021/050940 external-priority patent/WO2021209775A1/en
Publication of JP2023522193A publication Critical patent/JP2023522193A/ja
Publication of JPWO2021209775A5 publication Critical patent/JPWO2021209775A5/ja
Publication of JP2023522193A5 publication Critical patent/JP2023522193A5/ja
Pending legal-status Critical Current

Links

JP2022562752A 2020-04-17 2021-04-19 抗原プール Pending JP2023522193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170255.2 2020-04-17
EP20170255 2020-04-17
PCT/GB2021/050940 WO2021209775A1 (en) 2020-04-17 2021-04-19 Antigen pool

Publications (3)

Publication Number Publication Date
JP2023522193A JP2023522193A (ja) 2023-05-29
JPWO2021209775A5 JPWO2021209775A5 (https=) 2024-05-20
JP2023522193A5 true JP2023522193A5 (https=) 2024-05-20

Family

ID=70333816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562752A Pending JP2023522193A (ja) 2020-04-17 2021-04-19 抗原プール

Country Status (6)

Country Link
US (1) US20230302109A1 (https=)
EP (1) EP4136096A1 (https=)
JP (1) JP2023522193A (https=)
CN (1) CN115667288A (https=)
CA (1) CA3176754A1 (https=)
WO (1) WO2021209775A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
AT502292B1 (de) * 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
EP3576751A4 (en) * 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES
BR112021006941A2 (pt) * 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
AU2020302285A1 (en) * 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods
WO2021005338A2 (en) * 2019-07-05 2021-01-14 The Francis Crick Institute Limited Novel cancer antigens and methods
CN116057067A (zh) * 2020-04-17 2023-05-02 弗朗西斯·克里克研究所有限公司 用于治疗黑素瘤的ctl抗原的融合蛋白

Similar Documents

Publication Publication Date Title
JP2022540396A5 (https=)
JP2023522193A5 (https=)
CN305532029S (https=)
CN305533998S (https=)
CN305535024S (https=)
CN305534312S (https=)
CN305652203S (https=)
CN305535809S (https=)
CN305649225S (https=)
CN305647782S (https=)
CN305602222S (https=)
CN305531965S (https=)
CN305594750S (https=)
CN305598304S (https=)
CN305533720S (https=)
CN305597292S (https=)
CN305533508S (https=)
CN305533408S (https=)
CN305533366S (https=)
CN305532814S (https=)
CN305596250S (https=)
CN305595638S (https=)
CN305595485S (https=)
CN305595347S (https=)
CN305535494S (https=)